Erratum: Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia (International Journal of Neuropsychopharmacology (2015) 18: 6 (pyu117) DOI: 10.1093/ijnp/pyu117);Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia

International Journal of Neuropsychopharmacology

Volumn 18, Issue 6, 2015, Pages 1-9

  Goldstein, Meghan Elizabeth ^a,b   Anderson, Valerie Margaret ^b   Pillai, Avinesh ^b   Kydd, Robert R ^b   Russell, Bruce R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antipsychotic; Clozapine; Glutamate; Magnetic resonance imaging; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; BIOLOGICAL MARKER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRAIN REGION; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; DORSOLATERAL PREFRONTAL CORTEX; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; SCHIZOPHRENIA; TREATMENT RESPONSE; BRAIN; CASE CONTROL STUDY; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BIOMARKERS; BRAIN; CASE-CONTROL STUDIES; CLOZAPINE; CREATINE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939151295     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyad007     Document Type: Erratum

References (66)

1. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho B-C (2010) Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 67:255-262.
2. Aoyama N, Theberge J, Drost DJ, Manchanda R, Northcott S, Neufeld RWJ, Menon RS, Rajakumar N, Pavlosky WF, Densmore M, Schaefer B, Williamson PC (2011) Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry 198:448-456.
3. APA (2004) Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Arlington (VA): American Psychiatric Association.
4. Baddeley A, Emslie H, Nimmo-Smith I (1993) The Spot-the-Word test: a robust estimate of verbal intelligence based on lexical decision. Br J Clin Psychol 32:55-65.
5. Block W, Träber F, von Widdern O, Metten M, Schild H, Maier W, Zobel A, Jessen F (2009) Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int J Neuropsychopharmacology 12:415-422.
6. Brooks WM, Friedman SD, Stidley CA (1999) Reproducibility of 1H-MRS in vivo. Magn Reson Med 41:193-197.
7. Buckley PF, Krowinski AC, Miller DD, Friedman L, Eaton Y, Tronetti M (2001) Clinical and biochemical correlates of 'high-dose' clozapine therapy for treatment - refractory schizophrenia. Schizophr Res 49:225-227.
8. Bustillo J, Chen H, Jones T, Lemke N, Abbott C, Qualls C, Canive J, Gasparovic C (2014) Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. JAMA psychiatry (Chicago, Ill).
9. Bustillo JR, Lauriello J, Rowland LM, Jung RE, Petropoulos H, Hart BL, Blanchard J, Keith SJ, Brooks WM (2001) Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res 107:135-149.
10. Bustillo JR, Rowland LM, Jung R, Brooks WM, Qualls C, Hammond R, Hart B, Lauriello J (2008) Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 33:2456-2466.
11. Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C, Hammond R, Brooks WM, Lauriello J (2010) 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry 15:629-636.
12. Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, Apfeldorf W, Lauriello J, Posse S (2011) Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry 69:19-27.
13. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158:518-526.
14. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K (2007) Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry 62:1396-1404.
15. Conley RR, Kelly DL (2001) Management of treatment resistance in schizophrenia. Biol Psychiatry 50:898-911.
16. Currá MC, Pallotta BS (1996) Single-channel evidence for glycine and NMDA requirement in NMDA receptor activation. Brain Res 740:27-40.
17. de la Fuente-Sandoval C, Favila R, Alvarado P, Leon-Ortiz P, Diaz- Galvis L, Amezcua C, Garcia-Munoz E, Graff-Guerrero A (2009) Glutamate increase in the associative striatum in schizophrenia: a longitudinal magnetic resonance spectroscopy preliminary study. Gac Med Mex 145:109-113.
18. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, Mamo D, Ramirez-Bermudez J, Graff-Guerrero A (2011) Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 36:1781-1791.
19. de la Fuente-Sandoval C, León-Ortiz P, Azcárraga M, Stephano S, Favila R, Díaz-Galvis L, Alvarado-Alanis P, Ramírez-Bermúdez J, Graff-Guerrero A (2013) Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: A longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry 70:1057-1066.
20. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD (2012) Dopamine synthesis capacity in patients with treatmentresistant schizophrenia. Am J Psychiatry 169:1203-1210.
21. Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK (2014) Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry 75(5):e11-e13.
22. Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, Stone JM (2012) Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 37:2515-2521.
23. Ertugrul A, Volkan-Salanci B, Basar K, Karli Oguz K, Demir B, Ergun EL, Senturk S, Erbas B, Cila A, Ulug B (2009) The effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: relationship with treatment response. Psychiatry Research: Neuroimaging 174:121-129.
24. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC (2000) Placebo- controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157(5):826-828. PMID: 10784481.
25. Garcia M, Huppertz HJ, Ziyeh S, Buechert M, Schumacher M, Mader I (2009) Valproate-induced metabolic changes in patients with epilepsy: assessment with 1H-MRS. Epilepsia 50:486-492.
26. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ (2010) International Consensus Study of Antipsychotic Dosing. Am J Psychiatry 167:686-693.
27. Gordon E (2003) Integrative neuroscience. Neuropsychopharmacology 28 Suppl 1:S2-8.
28. Gordon E, Cooper N, Rennie C, Hermens D, Williams LM (2005) Integrative neuroscience: the role of a standardized database. Clin EEG Neurosci 36:64-75.
29. Goto N, Yoshimura R, Kakeda S, Nishimura J, Moriya J, Hayashi K, Katsuki A, Hori H, Umene-Nakano W, Ikenouchi-Sugita A (2012) Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr Dis Treat 8:119-122.
30. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment- refractory schizophrenia. Biol Psychiatry 57(6):577-585. PubMed PMID: 15780844.
31. Hetherington HP, Mason GF, Pan JW, Ponder SL, Vaughan JT, Twieg DB, Pohost GM (1994) Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1 T. Magn Reson Med 32:565-571.
32. Javitt DC, Duncan L, Balla A, Sershen H (2004) Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 10:275-287.
33. Kaiser LG, Schuff N, Cashdollar N, Weiner MW (2005) Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T. Neurobiol Aging 26:665-672.
34. Kanowski M, Kaufmann J, Braun J, Bernarding J, Tempelmann C (2004) Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med 51:904-912.
35. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia. Am J Psychiatry 157:514-520.
36. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
37. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, Gil R, Slifstein M, Abi-Dargham A, Lisanby SH, Shungu DC (2012) Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 69:449-459.
38. Kraguljac NV, Reid MA, White DM, den Hollander J, Lahti AC (2012a) Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology 37:2635-2642.
39. Kraguljac NV, Reid M, White D, Jones R, den Hollander J, Lowman D, Lahti AC (2012b) Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis. Psychiatry Res 203:111-125.
40. Kraguljac NV, White DM, Reid MA, Lahti AC (2013) Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 70:1294-1302.
41. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia from pathophysiology to treatment. Ann N Y Acad Sci 1003:138-158. PMID: 14684442.
42. Lieberman JA (1998) Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J Clin Psychiatry 60:9-12.
43. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234-242.
44. Marsman A, van den Heuvel MP, Klomp DWJ, Kahn RS, Luijten PR, Hulshoff Pol HE (2013) Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies. Schizophr Bull 39:120-129.
45. McIlwain ME, Harrison J, Wheeler AJ, Russell BR (2011) Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 7:135-149.
46. Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Olié JP, Lôo H, Gourion D (2006) Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol 29:28-33.
47. Mullins PG, Rowland L, Bustillo J, Bedrick EJ, Lauriello J, Brooks WM (2003) Reproducibility of 1H-MRS measurements in schizophrenic patients. Magn Reson Med 50:704-707.
48. NICE (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: National Institute for Clinical Excellence.
49. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
50. Poels EMP, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR (2014) Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. Schizophr Res 152:325-332.
51. Prescot AP, Locatelli AE, Renshaw PF, Yurgelun-Todd DA (2011) Neurochemical alterations in adolescent chronic marijuana smokers: A proton MRS study. Neuroimage 57:69-75.
52. Prescot AP, Renshaw PF, Yurgelun-Todd DA (2013) γ-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers. Drug Alcohol Depend 129:232-239.
53. Provencher SW (2001) Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14:260-264.
54. Royal Australian New Zealand College of Psychiatrists CPGTft- ToSRD (2005) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 39:1-30.
55. Schuff N, Ezekiel F, Gamst AC, Amend DL, Capizzano AA, Maudsley AA, Weiner MW (2001) Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging. Magn Reson Med 45:899-907.
56. Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G (2008) Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci 83:170-175.
57. Sesack SR, Carr DB, Omelchenko N, Pinto A (2003) Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann N Y Acad Sci 1003:36-52. PMID: 14684434.
58. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001) Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 24:330-334.
59. Shibuya-Tayoshi S, Tayoshi S, Sumitani S, Ueno S, Harada M, Ohmori T (2008) Lithium effects on brain glutamatergic and GABAergic systems of healthy volunteers as measured by proton magnetic resonance spectroscopy. Prog Neuropsychopharmacol Biol Psychiatry 32:249-256.
60. Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, Thompson RT (1996) An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull 22:597-609.
61. Szulc A, Galinska B, Tarasow E, Dzienis W, Kubas B, Konarzewska B, Walecki J, Alathiaki AS, Czernikiewicz A (2005) The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry 38:214-219.
62. Szulc A, Galinska B, Tarasow E, Waszkiewicz N, Konarzewska B, Poplawska R, Bibulowicz D, Simonienko K, Walecki J (2011) Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment. Pharmacopsychiatry 44:148-157.
63. Szulc A, Galinska-Skok B, Waszkiewicz N, Bibulowicz D, Konarzewska B, Tarasow E (2013) Proton magnetic resonance spectroscopy changes after antipsychotic treatment. Curr Med Chem 20:414-427.
64. Theberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK, Northcott S, Menon RS, Neufeld RWJ, Rajakumar N, Pavlosky W, Densmore M, Schaefer B, Williamson PC (2007) Longitudinal grey-matter and glutamatergic losses in firstepisode schizophrenia. Br J Psychiatry 191:325-334.
65. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44(11):1081-1089. PubMed PMID: 9836012.
66. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT (1999) D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 156(11):1822-1825. PMID: 10553752.